300558 贝达药业
交易中 02-24 13:46:24
资讯
新帖
简况
贝达药业最新公告：国家药监局批准帕妥珠单抗注射液上市
证券之星 · 02-06
贝达药业最新公告：国家药监局批准帕妥珠单抗注射液上市
贝达药业：恩沙替尼海外商业化工作正在稳步推进
证券之星 · 02-05
贝达药业：恩沙替尼海外商业化工作正在稳步推进
股市必读：贝达药业（300558）2月4日董秘有最新回复
证券之星 · 02-05
股市必读：贝达药业（300558）2月4日董秘有最新回复
贝达药业：MCLA-129与恩沙替尼联合用药I/II期临床研究已完成首例受试者入组
证券之星 · 02-04
贝达药业：MCLA-129与恩沙替尼联合用药I/II期临床研究已完成首例受试者入组
贝达药业：公司自研尚未有ADC产品项目立项
证券之星 · 02-04
贝达药业：公司自研尚未有ADC产品项目立项
贝达药业：股价波动受行业估值、市场情绪和资金博弈等多种因素影响
证券之星 · 02-04
贝达药业：股价波动受行业估值、市场情绪和资金博弈等多种因素影响
贝达药业最新公告：选举丁列明为董事长聘任多名高管
证券之星 · 02-01
贝达药业最新公告：选举丁列明为董事长聘任多名高管
贝达药业：目前公司扎实践行四驾马车发展战略
证券之星 · 01-29
贝达药业：目前公司扎实践行四驾马车发展战略
贝达药业：生态圈围绕新药产业、前沿科学、临床需求构建
证券之星 · 01-29
贝达药业：生态圈围绕新药产业、前沿科学、临床需求构建
股市必读：1月28日贝达药业现1笔折价20.85%的大宗交易 合计成交406.68万元
证券之星 · 01-29
股市必读：1月28日贝达药业现1笔折价20.85%的大宗交易 合计成交406.68万元
贝达药业：BPI-520105片是新型强效、高选择性泛表皮生长因子受体（Pan-EGFR）小分子抑制剂
证券之星 · 01-28
贝达药业：BPI-520105片是新型强效、高选择性泛表皮生长因子受体（Pan-EGFR）小分子抑制剂
贝达药业：RGB-5088胰岛细胞注射液已获批开展临床试验
证券之星 · 01-28
贝达药业：RGB-5088胰岛细胞注射液已获批开展临床试验
贝达药业：股票价格短期内波动受市场内的各种因素影响
证券之星 · 01-28
贝达药业：股票价格短期内波动受市场内的各种因素影响
贝达药业：恩沙替尼术后辅助适应症的临床研究目前仅在中国开展
证券之星 · 01-28
贝达药业：恩沙替尼术后辅助适应症的临床研究目前仅在中国开展
贝达药业：利用AI技术探索靶点发现与化合物筛选
证券之星 · 01-21
贝达药业：利用AI技术探索靶点发现与化合物筛选
1月21日贝达药业现1笔折价20.81%的大宗交易 合计成交489.7万元
中金财经 · 01-21
1月21日贝达药业现1笔折价20.81%的大宗交易 合计成交489.7万元
贝达药业：投资禾元生物公允价值变动不影响净利润
证券之星 · 01-21
贝达药业：投资禾元生物公允价值变动不影响净利润
贝达药业：打造四驾马车协同驱动的一体化平台
证券之星 · 01-21
贝达药业：打造四驾马车协同驱动的一体化平台
贝达药业：统筹推进EYP-1901国内临床研究及上市申报
证券之星 · 01-21
贝达药业：统筹推进EYP-1901国内临床研究及上市申报
1月14日贝达药业现1笔折价20.61%的大宗交易 合计成交590.67万元
证券之星 · 01-14
1月14日贝达药业现1笔折价20.61%的大宗交易 合计成交590.67万元
公司概况
公司名称：
贝达药业股份有限公司
所属行业：
医药制造业
上市日期：
2016-11-07
主营业务：
贝达药业股份有限公司的主营业务是创新药物的生产与销售。公司的主要产品是凯美纳、贝美纳、贝安汀、赛美纳、伏美纳、康美纳、安瑞泽、奥福民。
发行价格：
17.57
{"stockData":{"symbol":"300558","market":"SZ","secType":"STK","nameCN":"贝达药业","latestPrice":45.75,"timestamp":1771911984000,"preClose":45.86,"halted":0,"volume":3330302,"delay":0,"changeRate":-0.0024,"floatShares":419000000,"shares":421000000,"eps":0.7209,"marketStatus":"交易中","change":-0.11,"latestTime":"02-24 13:46:24","open":46.34,"high":46.4,"low":45.68,"amount":153000000,"amplitude":0.0157,"askPrice":45.75,"askSize":1,"bidPrice":45.74,"bidSize":78,"shortable":0,"etf":0,"ttmEps":0.7209,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1771916400000},"marketStatusCode":2,"adr":0,"adjPreClose":45.86,"symbolType":"stock","openAndCloseTimeList":[[1771896600000,1771903800000],[1771909200000,1771916400000]],"highLimit":50.45,"lowLimit":41.27,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":420733843,"isCdr":false,"pbRate":3.3,"roa":"--","peRate":63.462339,"roe":"5.5%","epsLYR":0.96,"committee":0.740913,"marketValue":19249000000,"turnoverRate":0.0079,"status":1,"floatMarketCap":19187000000},"requestUrl":"/m/hq/s/300558/wiki","defaultTab":"wiki","newsList":[{"id":"2609567222","title":"贝达药业最新公告：国家药监局批准帕妥珠单抗注射液上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2609567222","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609567222?lang=zh_cn&edition=full","pubTime":"2026-02-06 19:29","pubTimestamp":1770377364,"startTime":"0","endTime":"0","summary":"贝达药业(300558.SZ)公告称，公司收到国家药品监督管理局签发的《药品注册证书》，批准公司与杭州博之锐生物制药有限公司合作的帕妥珠单抗注射液（商品名：贝泽汀）上市。该药物适用于早期乳腺癌及转移性乳腺癌患者，是公司合作伙伴博锐生物自主研发的帕妥珠单抗生物类似药。截至公告披露日，国内共有三款治疗HER2阳性乳腺癌的帕妥珠单抗药物获批，贝泽汀属于生物类似药，注册分类为治疗用生物制品3.3类。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600035720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"gpt_icon":0},{"id":"2609704923","title":"贝达药业：恩沙替尼海外商业化工作正在稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2609704923","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609704923?lang=zh_cn&edition=full","pubTime":"2026-02-05 20:51","pubTimestamp":1770295914,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)02月04日在投资者关系平台上答复投资者关心的问题。投资者提问：恩沙美国全年有卖了几十万美元吗？bd又在哪里？？贝达药业回复：您好！恩沙替尼海外商业化工作正在稳步推进。战略合作是公司“四驾马车”发展战略的重要组成部分，按照“引进来，走出去”的工作思路，专业团队广泛对接全球优秀生物医药企业，积极探索多元化合作方式，如有重大进展公司会及时公告披露。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500037650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"gpt_icon":0},{"id":"2609392393","title":"股市必读：贝达药业（300558）2月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2609392393","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609392393?lang=zh_cn&edition=full","pubTime":"2026-02-05 02:16","pubTimestamp":1770228973,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘，贝达药业报收于46.71元，上涨0.69%，换手率0.9%，成交量3.77万手，成交额1.74亿元。董秘最新回复投资者： 百亿销售额的目标即将由闷声做事的艾力斯来实现？今日同行业艾力斯药业预增公告，预计2025年度营收52亿元，归属净利润21.5亿元。公司已按工作业务的相关进展预约2026年4月23日为2025年年度报告披露日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500001302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"gpt_icon":0},{"id":"2608351628","title":"贝达药业：MCLA-129与恩沙替尼联合用药I/II期临床研究已完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2608351628","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608351628?lang=zh_cn&edition=full","pubTime":"2026-02-04 17:03","pubTimestamp":1770195798,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业02月04日在投资者关系平台上答复投资者关心的问题。创新药的开发是一项长期的、艰巨的探索工作，MCLA-129作为EGFR/c-MET双特异性抗体，已在晚期非小细胞肺癌领域积累了颇具价值的临床数据。近日，MCLA-129与恩沙替尼联合用药I/II期临床研究已完成首例受试者入组，期待在与研究机构和专家们的共同努力下，进一步验证该联合治疗方案的临床潜力，为MET扩增或过表达晚期实体瘤患提供更多治疗选择。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400028245.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"gpt_icon":0},{"id":"2608351690","title":"贝达药业：公司自研尚未有ADC产品项目立项","url":"https://stock-news.laohu8.com/highlight/detail?id=2608351690","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608351690?lang=zh_cn&edition=full","pubTime":"2026-02-04 17:03","pubTimestamp":1770195797,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)02月04日在投资者关系平台上答复投资者关心的问题。投资者提问：据公开信息，公司多次提到布局ADC产品项目。请问董秘，这是自研产品还是从生态圈战略合作伙伴引进？贝达药业回复：您好！公司自研尚未有ADC产品项目立项，将通过生态圈联动合作伙伴积极关注ADC产品项目，后续如有相关重大节点进展，公司会及时公开披露。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400028244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","BK0060"],"gpt_icon":0},{"id":"2608351694","title":"贝达药业：股价波动受行业估值、市场情绪和资金博弈等多种因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2608351694","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608351694?lang=zh_cn&edition=full","pubTime":"2026-02-04 17:00","pubTimestamp":1770195651,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)02月04日在投资者关系平台上答复投资者关心的问题。投资者提问：原来五年新低在你们看来只是短期波动对吗？你们的短期居然能长达五年之久？贝达药业回复：您好！股价波动受行业估值、市场情绪和资金博弈等多种因素影响，从长期来看将回归公司自身价值。公司目前生产经营活动正常并始终聚焦核心业务，持续推进创新药研发与商业化，以稳健的经营、持续的增长夯实企业发展的基础，不断提升公司价值。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400028176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","BK0060"],"gpt_icon":0},{"id":"2608004669","title":"贝达药业最新公告：选举丁列明为董事长聘任多名高管","url":"https://stock-news.laohu8.com/highlight/detail?id=2608004669","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608004669?lang=zh_cn&edition=full","pubTime":"2026-02-01 16:50","pubTimestamp":1769935843,"startTime":"0","endTime":"0","summary":"贝达药业(300558.SZ)公告称，公司第五届董事会第一次会议选举丁列明为董事长，任期三年。同时，会议还审议通过了关于选举公司第五届董事会专门委员会的议案，以及聘任首席执行官、总经理、资深副总裁、研发总裁、行政总裁、副总裁、财务负责人、董事会秘书等其他高级管理人员的议案。此外，公司还修订、制定了部分治理制度，并修订了公司于H股发行并上市后适用的《公司章程（草案）》及相关议事规则（草案）。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100005588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300558"],"gpt_icon":0},{"id":"2607808226","title":"贝达药业：目前公司扎实践行四驾马车发展战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2607808226","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607808226?lang=zh_cn&edition=full","pubTime":"2026-01-29 20:48","pubTimestamp":1769690909,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业01月28日在投资者关系平台上答复投资者关心的问题。企业的发展是长期经营的根本，但股价的波动受市场内的各种因素影响。目前公司扎实践行四驾马车发展战略，聚焦未被满足的临床需求，积极推进在研管线项目，研发更多患者需要的好产品，全力推动企业发展，努力为股东创造价值。如有股东、董高增持股份计划或者回购计划，公司会根据相关法规要求及时公告披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900040721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","BK0060"],"gpt_icon":0},{"id":"2607783082","title":"贝达药业：生态圈围绕新药产业、前沿科学、临床需求构建","url":"https://stock-news.laohu8.com/highlight/detail?id=2607783082","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607783082?lang=zh_cn&edition=full","pubTime":"2026-01-29 20:48","pubTimestamp":1769690903,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业01月28日在投资者关系平台上答复投资者关心的问题。为实现优势互补、协同发展，促进人才、项目、信息及资金的互动及交流，公司以贝达药业主体为核心，医药产业基金、梦工场为两翼，围绕新药产业、前沿科学、临床需求，以共建、共享、开放、共赢的理念开展创新生态圈的构建工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900040710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300558"],"gpt_icon":0},{"id":"2607744191","title":"股市必读：1月28日贝达药业现1笔折价20.85%的大宗交易 合计成交406.68万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607744191","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607744191?lang=zh_cn&edition=full","pubTime":"2026-01-29 03:00","pubTimestamp":1769626838,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘，贝达药业报收于48.43元，上涨1.09%，换手率2.04%，成交量8.54万手，成交额4.17亿元。当日关注点来自交易信息汇总：1月28日主力资金净流入207.0万元，显示主力对贝达药业的阶段性青睐。来自交易信息汇总：当日发生一笔折价20.85%的大宗交易，合计成交406.68万元，反映部分股东减持意愿较强。大宗交易1月28日贝达药业现1笔折价20.85%的大宗交易，合计成交406.68万元。公司已预约2026年4月23日为2025年年度报告披露日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900001658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","BK0060"],"gpt_icon":0},{"id":"2606791568","title":"贝达药业：BPI-520105片是新型强效、高选择性泛表皮生长因子受体（Pan-EGFR）小分子抑制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2606791568","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606791568?lang=zh_cn&edition=full","pubTime":"2026-01-28 17:21","pubTimestamp":1769592070,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业01月28日在投资者关系平台上答复投资者关心的问题。公司自研的BPI-520105片是针对携带表皮生长因子受体突变实体瘤患者的新型强效、高选择性泛表皮生长因子受体小分子抑制剂；BPI-572270胶囊是拟用于治疗晚期恶性实体瘤患者的新型强效泛RAS“非降解型分子胶”抑制剂。目前，两个项目正按照临床研究计划有序推进，如有重大进展公司会及时履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800029282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0060","BK0239"],"gpt_icon":0},{"id":"2606799791","title":"贝达药业：RGB-5088胰岛细胞注射液已获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2606799791","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606799791?lang=zh_cn&edition=full","pubTime":"2026-01-28 17:18","pubTimestamp":1769591891,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业01月28日在投资者关系平台上答复投资者关心的问题。有人认为公司布局在瑞普晨创 解决血糖产生的源头问题。杭州瑞普晨创科技有限公司作为国内早期布局糖尿病细胞疗法的企业，其自主研发的用于治疗I型糖尿病的国内首款RGB-5088胰岛细胞注射液已获批开展临床试验。未来公司如与生态圈伙伴企业开展进一步重大合作的，公司将及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800029209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0060","BK0239"],"gpt_icon":1},{"id":"2606997927","title":"贝达药业：股票价格短期内波动受市场内的各种因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2606997927","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606997927?lang=zh_cn&edition=full","pubTime":"2026-01-28 17:15","pubTimestamp":1769591717,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)01月28日在投资者关系平台上答复投资者关心的问题。投资者提问：请问是什么原因导致你们对于投资者连续亏损五年的事情视而不见？贝达药业回复：您好！股票价格短期内波动受市场内的各种因素影响，我们始终相信长期来看股价更多取决于企业本身的价值成长。目前，公司始终以创新为核心，通过“自主研发、市场销售、战略合作和创新生态圈”四驾马车的战略引领，持续优化研发策略、提升研发效率，推动创新成果落地，努力不断为股东创造价值。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800029118.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"gpt_icon":0},{"id":"2606997767","title":"贝达药业：恩沙替尼术后辅助适应症的临床研究目前仅在中国开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2606997767","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606997767?lang=zh_cn&edition=full","pubTime":"2026-01-28 17:15","pubTimestamp":1769591716,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)01月28日在投资者关系平台上答复投资者关心的问题。投资者提问：＂恩沙替尼美国术后辅助适应症正处于临床数据落地 + 注册准备 + FDA 沟通的关键推进期，核心依托全球 III 期 ELEVATE 研究的阳性结果,由 Xcovery 主导美国申报!＂请问此消息是否属实？贝达药业回复：您好！恩沙替尼术后辅助适应症的临床研究目前仅在中国开展，后续如有该适应症的海外临床计划，公司会及时披露相关进展公告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800029115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"gpt_icon":0},{"id":"2605102570","title":"贝达药业：利用AI技术探索靶点发现与化合物筛选","url":"https://stock-news.laohu8.com/highlight/detail?id=2605102570","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605102570?lang=zh_cn&edition=full","pubTime":"2026-01-21 20:53","pubTimestamp":1768999994,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)01月21日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，AI在贝达研发方面是否得到应用，成果怎么样？AI研发有专门的科室吗？贝达药业回复：您好！公司密切关注AI技术在新药研发领域的应用，同时结合项目研发需求，利用内部和第三方资源在靶点发现、化合物筛选等环节开展探索性应用。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100039009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"gpt_icon":0},{"id":"2605610872","title":"1月21日贝达药业现1笔折价20.81%的大宗交易 合计成交489.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605610872","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605610872?lang=zh_cn&edition=full","pubTime":"2026-01-21 18:14","pubTimestamp":1768990448,"startTime":"0","endTime":"0","summary":"证券之星消息，1月21日贝达药业发生大宗交易，交易数据如下：大宗交易成交价格38.62元，相对当日收盘价折价20.81%，成交12.68万股，成交金额489.7万元，买方营业部为中信建投证券股份有限公司北京朝阳分公司，卖方营业部为中信建投证券股份有限公司北京朝阳分公司。近三个月该股共发生6笔大宗交易，合计成交8362.0手，折价成交6笔。截至2026年1月21日收盘，贝达药业报收于48.77元，上涨1.01%，换手率1.3%，成交量5.45万手，成交额2.66亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260121/31960670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","BK0060","300558"],"gpt_icon":0},{"id":"2605580127","title":"贝达药业：投资禾元生物公允价值变动不影响净利润","url":"https://stock-news.laohu8.com/highlight/detail?id=2605580127","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605580127?lang=zh_cn&edition=full","pubTime":"2026-01-21 12:33","pubTimestamp":1768969988,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)01月21日在投资者关系平台上答复投资者关心的问题。投资者提问：你好董秘 我司投资的禾元生物，按最近禾元生物市值，权益法计算，对我司净利润将带来20-25亿的增加。请问如果按权益法计算，我司净利润将暴增700％。为什么我司还不发布业绩预告？贝达药业回复：您好！公司对武汉禾元生物科技股份有限公司的投资计入其他权益工具投资科目核算，根据企业会计准则有关规定，将其公允价值变动计入其他综合收益科目，不影响公司净利润。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100017326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688765","300558"],"gpt_icon":0},{"id":"2605127531","title":"贝达药业：打造四驾马车协同驱动的一体化平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2605127531","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605127531?lang=zh_cn&edition=full","pubTime":"2026-01-21 12:33","pubTimestamp":1768969987,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业01月21日在投资者关系平台上答复投资者关心的问题。公司是一家专注于创新药物研究与开发的国家级高新制药企业，已打造自主研发、市场销售、战略合作与生态圈建设“四驾马车”协同驱动的一体化平台，成功商业化国内首款肺癌靶向创新药，并已陆续推出八款商业化产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100017325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"gpt_icon":0},{"id":"2605127539","title":"贝达药业：统筹推进EYP-1901国内临床研究及上市申报","url":"https://stock-news.laohu8.com/highlight/detail?id=2605127539","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605127539?lang=zh_cn&edition=full","pubTime":"2026-01-21 12:30","pubTimestamp":1768969830,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业01月21日在投资者关系平台上答复投资者关心的问题。投资者提问：为什么1901要等fda成功再引进国内，国内是有钱投仿制药也没钱做临床是吗？如果fda拒绝是不是1901就又没了？基于国外临床进展、国内商业化规划，公司将统筹推进EYP-1901的国内临床研究及上市申报工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100017319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0060","BK0239"],"gpt_icon":0},{"id":"2603699946","title":"1月14日贝达药业现1笔折价20.61%的大宗交易 合计成交590.67万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603699946","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603699946?lang=zh_cn&edition=full","pubTime":"2026-01-14 17:23","pubTimestamp":1768382630,"startTime":"0","endTime":"0","summary":"证券之星消息，1月14日贝达药业发生大宗交易，交易数据如下：大宗交易成交价格40.82元，相对当日收盘价折价20.61%，成交14.47万股，成交金额590.67万元，买方营业部为中信建投证券股份有限公司北京朝阳分公司，卖方营业部为中信建投证券股份有限公司北京朝阳分公司。近三个月该股共发生8笔大宗交易，合计成交9322.0手，折价成交8笔。截至2026年1月14日收盘，贝达药业报收于51.42元，上涨0.76%，换手率3.53%，成交量14.81万手，成交额7.65亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400029090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1771911988142,"stockEarnings":[{"period":"1week","weight":-0.0284},{"period":"1month","weight":-0.1081},{"period":"3month","weight":-0.1557},{"period":"6month","weight":-0.3269},{"period":"1year","weight":-0.1153},{"period":"ytd","weight":-0.0178}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0107},{"period":"3month","weight":0.0229},{"period":"6month","weight":0.1042},{"period":"1year","weight":0.2249},{"period":"ytd","weight":0.0285}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"贝达药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"34761人(较上一季度增加17.69%)","perCapita":"12065股","listingDate":"2016-11-07","address":"浙江省杭州市临平区经济技术开发区兴中路355号","registeredCapital":"42073万元","survey":" 贝达药业股份有限公司的主营业务是创新药物的生产与销售。公司的主要产品是凯美纳、贝美纳、贝安汀、赛美纳、伏美纳、康美纳、安瑞泽、奥福民。","listedPrice":17.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"贝达药业,300558,贝达药业股票,贝达药业股票老虎,贝达药业股票老虎国际,贝达药业行情,贝达药业股票行情,贝达药业股价,贝达药业股市,贝达药业股票价格,贝达药业股票交易,贝达药业股票购买,贝达药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}